After the bell Monday, Cepheid (CPHD) announced the first in a series of agreements with the Bill & Melinda Gates Foundation, the United States President's Emergency Plan for AIDS Relief, the United States Agency for International Development and UNITAID to buy-down the price of the Xpert MTB/RIF test in an effort to drive adoption of the technology as a critical tool in interrupting the transmission cycle of tuberculosis.
Cepheid has been rising sharply since the open of trade Tuesday and is now up 3.29 at $37.45. The stock has broken out to a 2 1/2 week high.
For comments and feedback: editorial@rttnews.com